• Silexion Therapeutics began GMP manufacturing of clinical supply for SIL204, positioning next-generation KRAS-targeting siRNA candidate for planned Phase 2/3 trial in locally advanced pancreatic cancer.
• No trial results have been presented; upcoming study is intended to generate safety and efficacy readouts, starting with safety run-in before moving to randomized stage.
• Manufactured batches are intended to support first patient dosing, reducing a key execution risk ahead of trial start.
• Tel Aviv Sourasky Medical Center ethics committee cleared site participation, strengthening near-term clinical start-up prospects alongside ongoing regulatory work in Israel and Germany.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605130800PRIMZONEFULLFEED1001181799) on May 13, 2026, and is solely responsible for the information contained therein.